Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update

- Recently announced interim data from ongoing MB-106 study demonstrating Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1(st) and 2(nd) line AML subjects (N=13)

- Also announced MB-106 reaches 20 subjects enrolled

- Company to host conference call and webcast today, Monday, May 13(th) at 8:30 AM ET

HOUSTON, May 13, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today reported its financial results for the quarter ended March 31, 2024. As previously announced, the Company will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 AM ET on Monday, May 13, 2024. (details below).

"We recently hosted a virtual AML Clinical Day featuring renowned KOLs, Dr. Martin Tallman and Dr. Michael Andreeff. It was great to hear their support of and thoughts on Annamycin's recent developments in AML. You can hear that discussion here. Combined with the encouraging Annamycin data demonstrated to date and the positive feedback from the KOLs, we continue to believe that our results in 2(nd) line subjects fill a significant unmet need. We believe this is supported by the exceptional CRc rate demonstrated by AnnAraC in 2(nd) line patients, which substantially exceeds the performance reported by any drug currently approved in the U.S. for use in 2(nd) line AML. We believe we are well-positioned for a highly productive End of Phase 2 meeting with FDA to discuss our planned pivotal study of Annamycin for AML," commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin.

Recent Highlights

    --  Bolstered the patent estate with issuance of U.S. patents. We recently
        received an Issue Notification from the United States Patent and
        Trademark Office (USPTO) for U.S. Patent number 11,980,634 titled,
        "Method of Reconstituting Liposomal Annamycin." Earlier, we received an
        Issue Notification titled, "Preparation of Preliposomal Annamycin
        Lyophilizate." Both provide claims to compositions that contain
        Annamycin with a base patent term extending until mid-2040.
    --  Hosted a virtual AML clinical day highlighting positive interim data for
        Annamycin from its ongoing acute myeloid leukemia (AML) clinical
        development program.
        --  Full MB-106 trial reaches 20 subjects with CRc of 45% in 1st - 7(th)
            line, with median durability at 4.9 months and climbing.
        --  1(st) and 2(nd) line patients reached a CRc rate of 62% and a CR
            rate of 54%.
        --  The 2(nd) line performance from the combination of Annamycin with
            Ara-C (AnnAraC) exceeds the approval data for all currently approved
            2(nd) line drugs.
        --  Interim data supports advancement to development of Phase 2
            registration-directed clinical trial (MB-108) to further provide
            data for efficacy to support an eventual application for New Drug
            Approval (NDA).
    --  Announced the formation of its Annamycin Scientific Advisory Board and
        inaugural appointment of Dr. Martin Tallman.
    --  Granted Orphan Drug Designation of Annamycin for the treatment of AML
        from the European Medicines Agency (EMA), adding to US Orphan Drug and
        Fast Track designations.
    --  Presented positive data demonstrating high anti-cancer activity of
        Annamycin and non-cardiotoxic properties at the American Association for
        Cancer Research (AACR) Annual Meeting.

Ongoing AML Clinical Trial Summary

The Company is currently conducting its Phase 1B/2 clinical trial evaluating Annamycin in combination with Cytarabine (also known as "Ara-C" and for which the combination of Annamycin and Ara-C is referred to as AnnAraC) for the treatment of subjects with AML as both first line therapy and for subjects who are refractory to or relapsed after induction therapy (MB-106). EudraCT 2020-005493-10 or NCT05319587.

A summary table of the MB-106 preliminary results is shown below. These subjects had 0-6 prior therapies. The preliminary data for MB-106 demonstrate a CRc rate of 45% and an overall remission rate (ORR) of 55% for all subjects, regardless of the number of prior treatments (N=20). Segmenting the MB-106 subject population for 1(st) line (N=3) and, most notably, 2(nd) line (N=10) therapies in the trial, yields a CRc rate of 67% and 60% and an ORR of 67% and 70%, both respectively.

Table 1 - Summary of Annamycin Remissions in MB-106 as of May 2, 2024

            Study MB-106 Combination Therapy -  All Lines  1st Line  2nd Line      1st and 2nd
                                                                         (Range                              Line
                                       Phase 1B/2 with               1-7)                             Combined
                                   Ara-C + Annamycin "5+3"

                All Subjects


       Recruited and Evaluable                                               20         3         10                13

       Subjects Evaluable Not Dosed Per Protocol                              2         0          1                 1

       Median Age - Years (Range)                                    69 (19-78)    49      71 (53 -
                                                                                  (19-69)       78)       67 (19-78)

       Complete Remissions (CR)                                               8         2          5                 7

       CR with incomplete recovery (CRi)                                      1         0          1                 1

       Total Composite Complete Remission (CRc)                               9         2          6                 8

       Complete Remission (CR) Rate                                        40 %     67 %      50 %             54 %

       Complete Remission Composite (CRc) Rate                             45 %     67 %      60 %             62 %

       Partial Remissions (PRs)                                               2         0          1                 1

       Overall Response Rate (CRc's + PRs) or ORR                          55 %     67 %      70 %             69 %

       CRc Relapsed or Death to Date                                          2         0          2                 2

       BMT To Date (in CR's)                                                  2         0          1                 1

        See Note 1 below

Notes for Table 1: Data from MB-106 is for Intent To Treat (ITT) subjects and is preliminary and subject to change.

Expected Milestones for Annamycin AML Development Program

    --  H1 2024: Complete MB-106 Phase 1B/2 clinical trial.
    --  H1 2024: MB-106 End of Phase 2 Meeting with FDA.
    --  H1 2025: Initiate pivotal trial.
    --  H2 2026: Feedback from the FDA EOP2 Meeting
    --  H2 2026: Conclude pivotal trial.
    --  2027: Potential NDA submission.

Summary of Financial Results for the First Quarter 2024

Research and development (R&D) expense was $4.3 million and $5.7 million for the three months ended March 31, 2024 and 2023, respectively. The decrease of $1.4 million is mainly related to the clinical trials activity levels.

General and administrative expense was $2.4 million and $2.6 million for the three months ended March 31, 2024 and 2023, respectively. The decrease of $0.2 million is mainly related to a decrease in regulatory and legal fees.

As of March 31, 2024, the Company had cash and cash equivalents of $16.8 million and believes that this cash is sufficient to meet its projected operating requirements, which includes the Company's current Phase 1B/2 clinical programs and preparations for future clinical trials, into the fourth quarter of 2024.

Conference Call and Webcast

Moleculin management will host its quarterly conference call and webcast for investors, analysts, and other interested parties Monday, May 13, 2024, at 8:30 AM ET.

Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing the Moleculin Biotech Conference Call. The live audio webcast will be accessible on the Events page of the Investors section of the Moleculin website,, and will be archived for 90 days.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. All interim and preliminary data discussed above are subject to change.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.

For more information about the Company, please visit and connect on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the Company's forecasted cash burn rate (including its estimate of cash sufficient to meet its projected operating requirements) and the achievement of the expected milestones set forth above. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including 'believes,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,' 'could,' 'might,' 'will,' 'should,' 'approximately' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:

Jenene Thomas
(833) 475-8247

                Moleculin Biotech, Inc.

                Unaudited Condensed Consolidated Balance Sheets

                (in thousands)                                                March 31, 2024                                   December 31, 2023

     Current assets:

     Cash and cash equivalents                                                               $16,824                                            $23,550

     Prepaid expenses and other current assets                                                 2,133                                              2,723

          Total current assets                                                                18,957                                             26,273

     Furniture and equipment, net                                                                240                                                272

     Intangible assets                                                                        11,148                                             11,148

     Operating lease right-of-use asset                                                          500                                                524

          Total assets                                                                       $30,845                                            $38,217

     Current liabilities:

     Accounts payable and accrued expenses and other current liabilities                      $5,408                                             $6,815

          Total current liabilities                                                            5,408                                              6,815

     Operating lease liability - long-term, net of current portion                               450                                                474

     Warrant liability - long term                                                             3,400                                              4,855

          Total liabilities                                                                    9,258                                             12,144

     Total stockholders' equity                                                               21,587                                             26,073

          Total liabilities and stockholders' equity                                         $30,845                                            $38,217

                Unaudited Condensed Consolidated Statements of Operations

                                                                                                     Three Months Ended March 31,

                (in thousands, except share and per share amounts)                            2024                                               2023

     $                    -       
              $                              -

     Operating expenses:

     Research and development                                                                  4,252                                              5,687

     General and administrative and depreciation and amortization                              2,425                                              2,667

          Total operating expenses                                                             6,677                                              8,354

     Loss from operations                                                                    (6,677)                                           (8,354)

     Other income:

     Gain from change in fair value of warrant liability                                       1,455                                                 39

     Other income, net                                                                            11                                                  8

     Interest income, net                                                                        241                                                392

     Net loss                                                                                (4,970)                                           (7,915)

     Net loss per common share - basic and diluted                                           $(2.02)                                           $(4.13)

     Weighted average common shares outstanding - basic and diluted                        2,466,174                                          1,916,665

View original content to download multimedia:

SOURCE Moleculin Biotech, Inc.